Stay connected! Share and follow:

Leukaemia CARE Careline

We're here to talk | 24-hours a day

08088 010 444

FREE from landlines & most major mobile networks

Dasatinib approved for CML patients in Scotland

written by

Leukaemia Care, Charity

  • PIXABAY-2552016-pills-1160893_1920

Earlier this week the Scottish Medicines Consortium (SMC) issued advice regarding the use of dasatinib within NHS Scotland, for the treatment of chronic myeloid leukaemia (CML). Dasatinib is marketed by Bristol-Myers Squibb as Sprycel®.

Chronic myeloid leukaemia (CML) is a rare form of leukaemia, with approximately 40-50 people diagnosed in Scotland each year. For more information on CML, please click here.

The SMC have recommended the use of dasatinib within NHS Scotland:

  1. “for the treatment of adult patients with newly diagnosed Philadelphia chromosome positive (Ph+) chronic myelogenous leukaemia (CML) in the chronic phase.”
  2. “for the treatment of adult patients with chronic, accelerated or blast phase chronic myelogenous leukaemia (CML) with resistance or intolerance to prior therapy including imatinib mesilate.”


Dasatinib is also currently being assessed by the National Institute for Health and Care Excellence (NICE), with a final decision expected in February 2017. In the meantime, it is currently funded via the Cancer Drugs Fund. More information on the ongoing NICE assessments is available here:

  1. First line – TA 251 -
  2. Second line – TA 241 -

Zack Pemberton-Whiteley, Head of Campaigns and Advocacy, Leukaemia CARE said:

“A diagnosis of chronic myeloid leukaemia, a rare form of blood cancer, can have a huge impact on the lives of patients and families that are affected. Today’s decision means that patients will now have access to an effective and convenient treatment with potential to improve their daily lives. This recommendation from the SMC is welcome news and a positive step forward for the treatment of this disease in Scotland.”

For further information, please contact our Campaigns and Advocacy team. They are available Monday to Friday from 9:00am – 5:30pm. If you would like to contact them, you can: